These clinical study results are supplied for informational purposes only in the interests of scientific disclosure. They are not intended to substitute for the FDA-approved package insert or other approved labeling. Drug Details Company Name Business Partner Drug Name Generic Name Unique ID Studied Indications or Disease Phase Approved Drug Label Eli Lilly and Company Permax pergolide tablets, USP 10245 (B001) Parkinson's Disease Phase IV http://www.fda.gov/cder/drug/advisory/pergolide.htm Clinical Study Summary Trial 10245 - (Publication Not Applicable) Observational Study to Determine the Incidence of New-Onset Cardiac Valvulopathy in Patients Treated With Pergolide as Second-Line Therapy for Parkinson's Disease Company Study Trial 10245 Observational Study to Determine the Incidence of New-Onset Cardiac Valvulopathy in Patients Treated With Pergolide as Second-Line Therapy for Parkinsons Disease Back to Search Results